Now, more than half a year later, the expansion plan for one of the company’s new facilities—a former magazine plant in ...
· In return for their investment in U.S. manufacturing, the administration would drop a proposed 100% tariffs on branded and patented drugs imported to the U.S. · Trump’s push for most-favored-nation ...
Regeneron is expanding its pharmaceutical production in New York, joining a wave of drug companies growing domestic ...
The FDA’s new Commissioner’s National Priority Voucher signals a transformative shift in U.S. drug review, tying accelerated approval to manufacturing readiness, domestic supply-chain strength, and ...
Having seen Congress spend money to onshore semiconductor production, pharma groups are pushing for similar incentives for ...
President Donald Trump on Monday signed an executive order to incentivize prescription drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build new production sites ...
Despite many overseas drugmakers gaining some tariff clarity when the U.S. | Thanks to a new accord with the United States, ...
Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company ...
Hosted on MSN
More tariffs by Trump: Branded pharma hit with 100% duty, and the list doesn't end there
US President Donald Trump has announced a new round of tariffs, slapping a 100% duty on pharmaceutical drugs from October 1, unless companies set up manufacturing plants in the United States.
President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers than others, according to some ...
Source: Getty Images If pharmaceutical manufacturers are hit with significant tariffs, there’s “a high probability” that drugs will be discontinued, according to Stephen Colvill, MBA. President Donald ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback